Short Interest in HeartSciences Inc. (NASDAQ:HSCS) Decreases By 18.2%

HeartSciences Inc. (NASDAQ:HSCS) was the recipient of a large decline in short interest during the month of April. As of April 15th, there was short interest totaling 28,778 shares, a decline of 18.2% from the March 31st total of 35,192 shares. Currently, 1.0% of the shares of the company are short sold. Based on an average trading volume of 14,161 shares, the short-interest ratio is currently 2.0 days.

Hedge Funds Weigh In On HeartSciences

A number of hedge funds and other institutional investors have recently made changes to their positions in HSCS. Geode Capital Management LLC bought a new position in shares of HeartSciences during the second quarter worth $43,000. TFB Advisors LLC bought a new position in shares of HeartSciences during the third quarter worth $105,000. Finally, DRW Securities LLC boosted its position in shares of HeartSciences by 13.7% during the fourth quarter. DRW Securities LLC now owns 95,065 shares of the company’s stock worth $294,000 after purchasing an additional 11,455 shares in the last quarter. 17.24% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of HeartSciences in a research note on Friday, March 27th. Ascendiant Capital Markets cut their target price on shares of HeartSciences from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Tuesday, March 24th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $8.00.

HeartSciences Trading Down 1.5%

Shares of NASDAQ HSCS traded down $0.03 during mid-day trading on Thursday, hitting $1.95. 24,297 shares of the stock were exchanged, compared to its average volume of 25,418. The stock’s fifty day simple moving average is $2.38 and its two-hundred day simple moving average is $2.77. The company has a debt-to-equity ratio of 0.16, a quick ratio of 1.04 and a current ratio of 1.19. HeartSciences has a twelve month low of $1.89 and a twelve month high of $6.47.

HeartSciences (NASDAQ:HSCS) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($0.84) by $0.21. As a group, equities research analysts forecast that HeartSciences will post -3.28 EPS for the current year.

HeartSciences Company Profile

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non?invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high?fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high?frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.